middle.news
Arovella clears manufacturing hurdle ahead of first ALA-101 dosing
8:27am on Friday 23rd of October, 2026 AEDT
•
Biotechnology
Read Story
Arovella clears manufacturing hurdle ahead of first ALA-101 dosing
8:27am on Friday 23rd of October, 2026 AEDT
Key Points
Two ALA-101 batches released for clinical use
The Alfred and Epworth sites activated and screening patients
First patient dosing expected in October 2026
ALA-105 solid tumour animal data due in coming weeks
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE